GARP: A surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing

Oncotarget

Volumn 7, Issue 27, 2016, Pages 42826-42836

  Sun, Liping ^a,b   Jin, Hao ^a,b   Li, Hui ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Glycoprotein A repetitions predominant; Regulatory T cells; Transforming growth factor

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; GLYCOPROTEIN; LRRC32 PROTEIN, HUMAN; MEMBRANE PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; CD4+ T LYMPHOCYTE; CELL MEMBRANE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; NEOPLASM; REGULATORY T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL MEMBRANE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HOMEOSTASIS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85014350642     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8753     Document Type: Review

References (113)

1. Schmetterer KG, Neunkirchner A and Pickl WF. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB journal. 2012; 26(6):2253-2276.
2. Bluestone JA and Abbas AK. Natural versus adaptive regulatory T cells. Nature reviews Immunology. 2003; 3(3):253-257.
3. Bilate AM and Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annual review of immunology. 2012; 30:733-758.
4. Horwitz DA, Zheng SG and Gray JD. Natural and TGFbeta- induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends in immunology. 2008; 29(9):429-435.
5. Chen X and Oppenheim JJ. Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. International immunopharmacology. 2011; 11(10):1489-1496.
6. Roubin R, Pizette S, Ollendorff V, Planche J, Birnbaum D and Delapeyriere O. Structure and developmental expression of mouse Garp, a gene encoding a new leucine rich repeat-containing protein. The International journal of developmental biology. 1996; 40(3):545-555.
7. Wang R, Wan Q, Kozhaya L, Fujii H and Unutmaz D. Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PloS one. 2008; 3(7):e2705.
8. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D and Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(32):13445-13450.
9. Stockis J, Colau D, Coulie PG and Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. European journal of immunology. 2009; 39(12):3315-3322.
10. Gershon RK and Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology. 1970; 18(5):723-737.
11. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of immunology. 1995; 155(3):1151-1164.
12. Suri-Payer E, Amar AZ, Thornton AM and Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. Journal of immunology. 1998; 160(3):1212-1218.
13. Almeida AR, Legrand N, Papiernik M and Freitas AA. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. Journal of immunology. 2002; 169(9):4850-4860.
14. Baecher-Allan C, Brown JA, Freeman GJ and Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. Journal of immunology. 2001; 167(3):1245-1253.
15. Baecher-Allan C, Viglietta V and Hafler DA. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. Journal of immunology. 2002; 169(11):6210-6217.
16. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD and Lechler RI. Human CD4(+) CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001; 98(9):2736-2744.
17. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T and Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008; 322(5899):271-275.
18. Redpath SA, van der Werf N, Cervera AM, MacDonald AS, Gray D, Maizels RM and Taylor MD. ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL- 10 production during helminth infection. European journal of immunology. 2013; 43(3):705-715.
19. van Mierlo GJ, Scherer HU, Hameetman M, Morgan ME, Flierman R, Huizinga TW and Toes RE. Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. Journal of immunology. 2008; 180(5):2747-2751.
20. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M and Byrne MC. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002; 16(2):311-323.
21. Hamano R, Huang J, Yoshimura T, Oppenheim JJ and Chen X. TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. European journal of immunology. 2011; 41(7):2010-2020.
22. Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, Parmiani G, Belli F, Rivoltini L and Castelli C. LAG-3 expression defines a subset of CD4(+)CD25(high) Foxp3(+) regulatory T cells that are expanded at tumor sites. Journal of immunology. 2010; 184(11):6545-6551.
23. Tran DQ, Andersson J, Hardwick D, Bebris L, Illei GG and Shevach EM. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/ CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood. 2009; 113(21):5125-5133.
24. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG and Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005; 22(3):329-341.
25. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y and Shevach EM. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. Journal of immunology. 2010; 184(7):3433-3441.
26. Hartigan-O'Connor DJ, Poon C, Sinclair E and McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. Journal of immunological methods. 2007; 319(1-2):41-52.
27. Garcia Santana CA, Tung JW and Gulnik S. Human treg cells are characterized by low/negative CD6 expression. Cytometry Part A. 2014; 85(10):901-908.
28. Salgado FJ, Perez-Diaz A, Villanueva NM, Lamas O, Arias P and Nogueira M. CD26: a negative selection marker for human Treg cells. Cytometry Part A. 2012; 81(10):843-855.
29. Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rotzschke O and Falk K. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood. 2009; 113(4):827-836.
30. Williams LM and Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nature immunology. 2007; 8(3):277-284.
31. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG and Levings MK. Activationinduced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. International immunology. 2007; 19(4):345-354.
32. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG and Levings MK. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. The Journal of clinical investigation. 2005; 115(11):3276-3284.
33. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD and Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(17):6659-6664.
34. Tran DQ, Ramsey H and Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007; 110(8):2983-2990.
35. Ramsdell F and Ziegler SF. FOXP3 and scurfy: how it all began. Nature reviews Immunology. 2014; 14(5):343-349.
36. Noyan F, Lee YS, Zimmermann K, Hardtke-Wolenski M, Taubert R, Warnecke G, Knoefel AK, Schulde E, Olek S, Manns MP and Jaeckel E. Isolation of human antigenspecific regulatory T cells with high suppressive function. European journal of immunology. 2014; 44(9):2592-2602.
37. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H and Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(32):13439-13444.
38. Zhou AX, Kozhaya L, Fujii H and Unutmaz D. GARPTGF- beta complexes negatively regulate regulatory T cell development and maintenance of peripheral CD4+ T cells in vivo. Journal of immunology. 2013; 190(10):5057-5064.
39. Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K and Rudensky AY. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 2010; 463(7282):808-812.
40. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, Scheffold A and Thiel A. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nature medicine. 2005; 11(10):1118-1124.
41. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW and Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyteassociated antigen 4. The Journal of experimental medicine. 2000; 192(2):303-310.
42. Burmeister Y, Lischke T, Dahler AC, Mages HW, Lam KP, Coyle AJ, Kroczek RA and Hutloff A. ICOS controls the pool size of effector-memory and regulatory T cells. Journal of immunology. 2008; 180(2):774-782.
43. Vocanson M, Rozieres A, Hennino A, Poyet G, Gaillard V, Renaudineau S, Achachi A, Benetiere J, Kaiserlian D, Dubois B and Nicolas JF. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells. The Journal of allergy and clinical immunology. 2010; 126(2):280-289, 289.e281-287.
44. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, Qin FX, Gilliet M and Liu YJ. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity. 2008; 28(6):870-880.
45. Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN and Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. Journal of immunology. 2008; 180(10):6467-6471.
46. Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM and Oppenheim JJ. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. Journal of immunology. 2010; 185(1):174-182.
47. Shimizu J, Yamazaki S, Takahashi T, Ishida Y and Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nature immunology. 2002; 3(2):135-142.
48. Liao G, Detre C, Berger SB, Engel P, de Waal Malefyt R, Herzog RW, Bhan AK and Terhorst C. Glucocorticoidinduced tumor necrosis factor receptor family-related protein regulates CD4(+)T cell-mediated colitis in mice. Gastroenterology. 2012; 142(3):582-591.e588.
49. Schoenbrunn A, Frentsch M, Kohler S, Keye J, Dooms H, Moewes B, Dong J, Loddenkemper C, Sieper J, Wu P, Romagnani C, Matzmohr N and Thiel A. A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. Journal of immunology. 2012; 189(12):5985-5994.
50. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nature reviews Immunology. 2009; 9(4):271-285.
51. Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG and Vignali DA. Role of LAG-3 in regulatory T cells. Immunity. 2004; 21(4):503-513.
52. Workman CJ, Rice DS, Dugger KJ, Kurschner C and Vignali DA. Phenotypic analysis of the murine CD4- related glycoprotein, CD223 (LAG-3). European journal of immunology. 2002; 32(8):2255-2263.
53. D'Ambrosio A, Cossu A, Amendola A, Zandri A, Butera A, Sanchez M, Biffoni M, Pronio A, Montesani C, Kohn A, Pica R and Boirivant M. Lamina propria CD4+LAP+ regulatory T cells are increased in active ulcerative colitis but show increased IL-17 expression and reduced suppressor activity. Journal of Crohn's & colitis. 2016; 10:346-53. doi: 10.1093/ecco-jcc/jjv216.
54. Simonetta F, Chiali A, Cordier C, Urrutia A, Girault I, Bloquet S, Tanchot C and Bourgeois C. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. European journal of immunology. 2010; 40(9):2528-2538.
55. Himmel ME, MacDonald KG, Garcia RV, Steiner TS and Levings MK. Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. Journal of immunology. 2013; 190(5):2001-2008.
56. Ollendorff V, Szepetowski P, Mattei MG, Gaudray P and Birnbaum D. New gene in the homologous human 11q13-q14 and mouse 7F chromosomal regions. Mammalian genome. 1992; 2(3):195-200.
57. Seldin MF, Saunders AM, Rochelle JM and Howard TA. A proximal mouse chromosome 9 linkage map that further defines linkage groups homologous with segments of human chromosomes 11, 15, and 19. Genomics. 1991; 9(4):678-685.
58. Ollendorff V, Noguchi T, deLapeyriere O and Birnbaum D. The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. Cell growth & differentiation. 1994; 5(2):213-219.
59. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, Gusnanto A, Steward M, Burns P, Langford CF, Ellis PD, Dudbridge F, Zwaginga JJ, Watkins NA, van der Schoot CE and Ouwehand WH. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 2007; 109(8):3260-3269.
60. Carrillo-Galvez AB, Cobo M, Cuevas-Ocana S, Gutierrez- Guerrero A, Sanchez-Gilabert A, Bongarzone P, Garcia- Perez A, Munoz P, Benabdellah K, Toscano MG, Martin F and Anderson P. Mesenchymal stromal cells express GARP/LRRC32 on their surface: effects on their biology and immunomodulatory capacity. Stem cells. 2015; 33(1):183-195.
61. Liu CJ, Lin SC, Chen YJ, Chang KM and Chang KW. Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Molecular carcinogenesis. 2006; 45(10):721-731.
62. Martinez-Cardus A, Martinez-Balibrea E, Bandres E, Malumbres R, Gines A, Manzano JL, Taron M, Garcia- Foncillas J and Abad A. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Molecular cancer therapeutics. 2009; 8(1):194-202.
63. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U and Werner M. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. Journal of molecular medicine. 2007; 85(3):293-304.
64. Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, Ursule L, Kouzarides T and Theillet C. Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clinical cancer research. 2004; 10(17):5785-5791.
65. Hickey MJ, Hagen FS, Yagi M and Roth GJ. Human platelet glycoprotein V: characterization of the polypeptide and the related Ib-V-IX receptor system of adhesive, leucine-rich glycoproteins. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(18):8327-8331.
66. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM and Davies DR. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(31):10976-10980.
67. Probst-Kepper M, Geffers R, Kroger A, Viegas N, Erck C, Hecht HJ, Lunsdorf H, Roubin R, Moharregh-Khiabani D, Wagner K, Ocklenburg F, Jeron A, Garritsen H, Arstila TP, Kekalainen E, Balling R, et al. GARP: a key receptor controlling FOXP3 in human regulatory T cells. Journal of cellular and molecular medicine. 2009; 13(9b):3343-3357.
68. Yang Y, Liu B, Dai J, Srivastava PK, Zammit DJ, Lefrancois L and Li Z. Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. Immunity. 2007; 26(2):215-226.
69. Zhang Y, Wu BX, Metelli A, Thaxton JE, Hong F, Rachidi S, Ansa-Addo E, Sun S, Vasu C, Yang Y, Liu B and Li Z. GP96 is a GARP chaperone and controls regulatory T cell functions. The Journal of clinical investigation. 2015; 125(2):859-869.
70. Ernst A, Appleton BA, Ivarsson Y, Zhang Y, Gfeller D, Wiesmann C and Sidhu SS. A structural portrait of the PDZ domain family. Journal of molecular biology. 2014; 426(21):3509-3519.
71. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflammation research. 2010; 59(10):791-808.
72. Li Y, Kim BG, Qian S, Letterio JJ, Fung JJ, Lu L and Lin F. Hepatic Stellate Cells Inhibit T Cells through Active TGFbeta1 from a Cell Surface-Bound Latent TGF-beta1/GARP Complex. Journal of immunology. 2015; 195(6):2648-2656.
73. Wang R, Zhu J, Dong X, Shi M, Lu C and Springer TA. GARP regulates the bioavailability and activation of TGFbeta. Molecular biology of the cell. 2012; 23(6):1129-1139.
74. Rappl G, Pabst S, Riemann D, Schmidt A, Wickenhauser C, Schutte W, Hombach AA, Seliger B, Grohe C and Abken H. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clinical immunology. 2011; 140(1):71-83.
75. Zhong Y, Tang H, Wang X, Zeng Q, Liu Y, Zhao X, Yu K, Shi H, Zhu R and Mao X. Intranasal Immunization with Heat Shock Protein 60 Induces CD4+CD25+GARP+ and Type-1 Regulatory T Cells and Inhibits Early Atherosclerosis. Clinical and experimental immunology. 2016; 183:452-68. doi: 10.1111/cei.12726.
76. Reinwald S, Wiethe C, Westendorf AM, Breloer M, Probst-Kepper M, Fleischer B, Steinkasserer A, Buer J and Hansen W. CD83 expression in CD4+ T cells modulates inflammation and autoimmunity. Journal of immunology. 2008; 180(9):5890-5897.
77. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE and Ansell SM. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood. 2007; 110(7):2537-2544.
78. Eschborn M, Weigmann B, Reissig S, Waisman A, Saloga J and Bellinghausen I. Activated glycoprotein A repetitions predominant (GARP)-expressing regulatory T cells inhibit allergen-induced intestinal inflammation in humanized mice. The Journal of allergy and clinical immunology. 2015; 136(1):159-168.
79. Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A and Sallusto F. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. The Journal of experimental medicine. 2005; 201(11):1793-1803.
80. Elkord E, Abd Al Samid M and Chaudhary B. Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP. Oncotarget. 2015; 6(24):20026-20036. doi: 10.18632/oncotarget.4771.
81. Edwards JP, Fujii H, Zhou AX, Creemers J, Unutmaz D and Shevach EM. Regulation of the expression of GARP/ latent TGF-beta1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. Journal of immunology. 2013; 190(11):5506-5515.
82. Lee SY, Cho ML, Oh HJ, Ryu JG, Park MJ, Jhun JY, Park MK, Stone JC, Ju JH, Hwang SY, Park SH, Surh CD and Kim HY. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Immunology. 2012; 137(4):305-316.
83. Buscemi L, Ramonet D, Klingberg F, Formey A, Smith- Clerc J, Meister JJ and Hinz B. The single-molecule mechanics of the latent TGF-beta1 complex. Current biology. 2011; 21(24):2046-2054.
84. Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. The Journal of biological chemistry. 2005; 280(9):7409-7412.
85. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T and Springer TA. Latent TGF-beta structure and activation. Nature. 2011; 474(7351):343-349.
86. Wipff PJ and Hinz B. Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. European journal of cell biology. 2008; 87(8-9):601-615.
87. Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P, Todorovic V, Dabovic B and Rifkin DB. Perturbation of transforming growth factor (TGF)-beta1 association with latent TGFbeta binding protein yields inflammation and tumors. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(48):18758-18763.
88. Worthington JJ, Klementowicz JE and Travis MA. TGFbeta: a sleeping giant awoken by integrins. Trends in biochemical sciences. 2011; 36(1):47-54.
89. Gauthy E, Cuende J, Stockis J, Huygens C, Lethe B, Collet JF, Bommer G, Coulie PG and Lucas S. GARP is regulated by miRNAs and controls latent TGF-beta1 production by human regulatory T cells. PloS one. 2013; 8(9):e76186.
90. Giacomini MM, Travis MA, Kudo M and Sheppard D. Epithelial cells utilize cortical actin/myosin to activate latent TGF-beta through integrin alpha(v)beta(6)- dependent physical force. Experimental cell research. 2012; 318(6):716-722.
91. Paidassi H, Acharya M, Zhang A, Mukhopadhyay S, Kwon M, Chow C, Stuart LM, Savill J and Lacy-Hulbert A. Preferential expression of integrin alphavbeta8 promotes generation of regulatory T cells by mouse CD103+ dendritic cells. Gastroenterology. 2011; 141(5):1813-1820.
92. Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA and Sheppard D. Loss of integrin alpha(v) beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature. 2007; 449(7160):361-365.
93. Edwards JP, Thornton AM and Shevach EM. Release of active TGF-beta1 from the latent TGF-beta1/GARP complex on T regulatory cells is mediated by integrin beta8. Journal of immunology. 2014; 193(6):2843-2849.
94. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H and Strober W. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. Journal of immunology. 2004; 172(2):834-842.
95. Li MO, Wan YY and Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007; 26(5):579-591.
96. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H and Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(2):419-424.
97. Mempel TR, Pittet MJ, Khazaie K, Weninger W, Weissleder R, von Boehmer H and von Andrian UH. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity. 2006; 25(1):129-141.
98. Shen E, Zhao K, Wu C and Yang B. The suppressive effect of CD25+Treg cells on Th1 differentiation requires cellcell contact partially via TGF-beta production. Cell biology international. 2011; 35(7):705-712.
99. Nakamura K, Kitani A and Strober W. Cell contactdependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. The Journal of experimental medicine. 2001; 194(5):629-644.
100. Gregg RK, Jain R, Schoenleber SJ, Divekar R, Bell JJ, Lee HH, Yu P and Zaghouani H. A sudden decline in active membrane-bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. Journal of immunology. 2004; 173(12):7308-7316.
101. Miller MM, Fogle JE, Ross P and Tompkins MB. Feline glycoprotein A repetitions predominant anchors transforming growth factor beta on the surface of activated CD4(+)CD25(+) regulatory T cells and mediates AIDS lentivirus-induced T cell immunodeficiency. AIDS research and human retroviruses. 2013; 29(4):641-651.
102. Miller MM, Petty CS, Tompkins MB and Fogle JE. CD4+CD25+ T regulatory cells activated during feline immunodeficiency virus infection convert T helper cells into functional suppressors through a membrane-bound TGFbeta / GARP-mediated mechanism. Virology journal. 2014; 11:7.
103. Cuende J, Lienart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, Baron F, Dumoutier L, Renauld JC, De Haard H, Saunders M, et al. Monoclonal antibodies against GARP/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science translational medicine. 2015; 7(284):284ra256.
104. Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S and Chen W. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nature immunology. 2008; 9(6):632-640.
105. Stockis J, Fink W, Francois V, Connerotte T, de Smet C, Knoops L, van der Bruggen P, Boon T, Coulie PG and Lucas S. Comparison of stable human Treg and Th clones by transcriptional profiling. European journal of immunology. 2009; 39(3):869-882.
106. Lu L, Wang J, Zhang F, Chai Y, Brand D, Wang X, Horwitz DA, Shi W and Zheng SG. Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells. Journal of immunology. 2010; 184(8):4295-4306.
107. Tone Y, Furuuchi K, Kojima Y, Tykocinski ML, Greene MI and Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nature immunology. 2008; 9(2):194-202.
108. Schlenner SM, Weigmann B, Ruan Q, Chen Y and von Boehmer H. Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut. The Journal of experimental medicine. 2012; 209(9):1529-1535.
109. Ouyang W, Beckett O, Ma Q and Li MO. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity. 2010; 32(5):642-653.
110. Pastille E, Bardini K, Fleissner D, Adamczyk A, Frede A, Wadwa M, von Smolinski D, Kasper S, Sparwasser T, Gruber AD, Schuler M, Sakaguchi S, Roers A, Muller W, Hansen W, Buer J, et al. Transient ablation of regulatory T cells improves antitumor immunity in colitis-associated colon cancer. Cancer research. 2014; 74(16):4258-4269.
111. Schuler PJ, Harasymczuk M, Schilling B, Saze Z, Strauss L, Lang S, Johnson JT and Whiteside TL. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clinical cancer research. 2013; 19(23):6585-6596.
112. Kalathil S, Lugade AA, Miller A, Iyer R and Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer research. 2013; 73(8):2435-2444.
113. Laurent C, Muller S, Do C, Al-Saati T, Allart S, Larocca LM, Hohaus S, Duchez S, Quillet-Mary A, Laurent G, Brousset P and Valitutti S. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood. 2011; 118(20):5371-5379.